Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 28;8(7):674.
doi: 10.3390/jof8070674.

Isavuconazole for COVID-19-Associated Invasive Mold Infections

Nadir Ullah  1 , Chiara Sepulcri  1   2 , Malgorzata Mikulska  1   2
Affiliations
Review

Isavuconazole for COVID-19-Associated Invasive Mold Infections

Nadir Ullah et al. J Fungi (Basel). .

Abstract

Isavuconazole is a broad-spectrum antifungal drug recently approved as a first-line treatment for invasive aspergillosis and as a first or alternative treatment for mucormycosis. The purpose of this review was to report and discuss the use of isavuconazole for the treatment of COVID-19-associated aspergillosis (CAPA), and COVID-19-associated mucormycosis (CAM). Among all studies which reported treatment of CAPA, approximately 10% of patients were reportedly treated with isavuconazole. Considering 14 identified studies that reported the use of isavuconazole for CAPA, isavuconazole was used in 40% of patients (95 of 235 treated patients), being first-line monotherapy in over half of them. We identified six studies that reported isavuconazole use in CAM, either alone or in combination therapy. Overall, isavuconazole was used as therapy in 13% of treated CAM patients, frequently as combination or sequential therapy. The use of isavuconazole in CAPA and CAM is complicated by the challenge of achieving adequate exposure in COVID-19 patients who are frequently obese and hospitalized in the ICU with concomitant renal replacement therapy (RRT) or extracorporeal membrane oxygenation (ECMO). The presence of data on high efficacy in the treatment of aspergillosis, lower potential for drug-drug interactions (DDIs) and for subtherapeutic levels, and no risk of QT prolongation compared to other mold-active azoles, better safety profile than voriconazole, and the possibility of using an intravenous formulation in the case of renal failure are the advantages of using isavuconazole in this setting.

Keywords: CAM; CAPA; COVID-19; ECMO; RRT; TDM; aspergillosis; invasive fungal infection; isavuconazole; mucormycosis.

PubMed Disclaimer

Conflict of interest statement

MM has received speaker fees from Janssen, Gilead, MSD and Pfizer; none related to this work. EC has received speaker fees from Gilead, Pfizer, Mundibiopharma, Astellas; none related to this work. All other authors: nothing to declare.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Schauwvlieghe A.F., Rijnders B.J., Philips N., Verwijs R., Vanderbeke L., Van Tienen C., Lagrou K., Verweij P.E., Van de Veerdonk F.L., Gommers D. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: A retrospective cohort study. Lancet Respir. Med. 2018;6:782–792. doi: 10.1016/S2213-2600(18)30274-1. - DOI - PubMed
    1. Arastehfar A., Carvalho A., Nguyen M.H., Hedayati M.T., Netea M.G., Perlin D.S., Hoenigl M. COVID-19-associated candidiasis (CAC): An underestimated complication in the absence of immunological predispositions? J. Fungi. 2020;6:211. doi: 10.3390/jof6040211. - DOI - PMC - PubMed
    1. Rutsaert L., Steinfort N., Van Hunsel T., Bomans P., Naesens R., Mertes H., Dits H., Van Regenmortel N. COVID-19-associated invasive pulmonary aspergillosis. Ann. Intensive Care. 2020;10:71. doi: 10.1186/s13613-020-00686-4. - DOI - PMC - PubMed
    1. van de Veerdonk F.L., Brüggemann R.J., Vos S., De Hertogh G., Wauters J., Reijers M.H., Netea M.G., Schouten J.A., Verweij P.E. COVID-19-associated Aspergillus tracheobronchitis: The interplay between viral tropism, host defence, and fungal invasion. Lancet Respir. Med. 2021;9:795–802. doi: 10.1016/S2213-2600(21)00138-7. - DOI - PMC - PubMed
    1. Feys S., Almyroudi M.P., Braspenning R., Lagrou K., Spriet I., Dimopoulos G., Wauters J. A Visual and Comprehensive Review on COVID-19-Associated Pulmonary Aspergillosis (CAPA) J. Fungi. 2021;7:1067. doi: 10.3390/jof7121067. - DOI - PMC - PubMed

Grants and funding

This research received no external funding.

LinkOut - more resources